Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood: a Multi-center, Prospective Study
Second Affiliated Hospital, School of Medicine, Zhejiang University
600 participants
Feb 5, 2024
OBSERVATIONAL
Conditions
Summary
By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.
Eligibility
Inclusion Criteria5
- Voluntarily sign informed consent.
- Male or female, age equal to or greater than 18 years and less than 75 years.
- Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection
- The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc.
- Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma.
Exclusion Criteria5
- Female subjects who are pregnant or breastfeeding.
- Previous organ transplantation or non-autologous bone marrow or stem cell transplantation.
- Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc.
- History of previous malignant tumors.
- Having other malignant tumors or multiple primary tumors at the same time.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Proteomic is performed on all blood samples.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06544083